Medical professionals have commended the remarkable efficacy of a treatment that completely eliminated tumors in cancer patients who had previously shown resistance to standard therapies. A recent trial conducted at the Institute of Cancer Research (ICR) in London demonstrated a 42% reduction in tumor size for participants.
During the peak of his battle with tongue cancer, Carl Walsh’s diet consisted mainly of soft foods like soup, rice pudding, and tinned ravioli, supplemented by three prescribed nutritional milk drinks each day. Walsh, 56, shared his struggles with speaking and eating due to swelling and pain, resulting in significant weight loss.
Walsh was one of 102 individuals with head and neck cancer enrolled in a study at The Royal Marsden hospital in London, investigating a promising triple-action cancer treatment. The research team celebrated unprecedented outcomes, noting instances where tumors completely vanished following the injection.
The drug, amivantamab, is administered every three weeks and works by targeting the EGFR protein crucial for cancer growth, blocking the MET pathway used by tumor cells to resist treatment, and stimulating the immune system to attack cancer cells.
Initially treated with chemotherapy and immunotherapy without success, Walsh was recommended for the OrigAMI-4 trial after which he experienced a rapid return to a normal diet and substantial improvement in speech and overall well-being.
Of the patients receiving amivantamab, 42% observed tumor shrinkage, with 15 individuals experiencing complete tumor disappearance. These patients survived an average of 12.5 months after beginning treatment, despite facing poor prognoses with conventional therapies.
Professor Kevin Harrington, an expert in biological cancer therapies at The ICR and consultant at The Royal Marsden, lauded the unprecedented positive responses seen in patients resistant to traditional treatments. The treatment’s potential benefits for a significant number of patients in the UK and Europe were highlighted.
Approximately 12,800 individuals in the UK receive a head and neck cancer diagnosis annually. Although amivantamab has already received NHS approval for certain non-small-cell lung cancer patients, ongoing clinical trials worldwide, including approximately 60 trials focusing on various cancers, are assessing its effectiveness.
ICR’s chief executive, Professor Kristian Helin, emphasized the study’s significance in advancing treatments for patients with limited options, showcasing the potential impact of rigorous cancer research in driving meaningful progress.
The groundbreaking research was presented at the American Society of Clinical Oncology’s annual conference in Chicago, underscoring the importance of continuous innovation in cancer treatment.
